Exact Sciences Corporation (EXAS) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Medical - Diagnostics & Research Branche. Der Hauptsitz des Unternehmens ist in Madison, WI, United States. Der aktuelle CEO ist Kevin T. Conroy.
EXAS hat IPO-Datum 2001-02-01, 6,900 Vollzeitbeschäftigte, gelistet an der NASDAQ Capital Marke, eine Marktkapitalisierung von $20.03B.
Exact Sciences Corporation is a leading provider of cancer screening and diagnostic testing solutions operating across the United States and international markets. The company's flagship product, Cologuard, is a non-invasive stool-based DNA test designed to detect colorectal cancer and pre-cancerous conditions by identifying specific DNA and hemoglobin biomarkers. Beyond screening, Exact Sciences offers a comprehensive portfolio of diagnostic tests including Oncotype DX for gene expression analysis in breast, prostate, and colon cancers, as well as advanced tumor profiling and liquid-based testing solutions for metastatic and refractory cancers. The company maintains strategic partnerships with the Mayo Foundation for Medical Education and Research and Hologic, Inc., while its development pipeline focuses on enhancing existing tests and expanding into blood-based and other fluid diagnostic platforms. Founded in 1995 and headquartered in Madison, Wisconsin, Exact Sciences continues to advance precision oncology and cancer prevention.
